Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 167.75
IMGN's Cash-to-Debt is ranked higher than
52% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. IMGN: 167.75 )
Ranked among companies with meaningful Cash-to-Debt only.
IMGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39  Med: No Debt Max: 50356.33
Current: 167.75
0.39
50356.33
Equity-to-Asset 0.23
IMGN's Equity-to-Asset is ranked lower than
87% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. IMGN: 0.23 )
Ranked among companies with meaningful Equity-to-Asset only.
IMGN' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.03  Med: 0.73 Max: 0.96
Current: 0.23
-1.03
0.96
Debt-to-Equity 0.02
IMGN's Debt-to-Equity is ranked higher than
91% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. IMGN: 0.02 )
Ranked among companies with meaningful Debt-to-Equity only.
IMGN' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.17  Med: 0.02 Max: 1.53
Current: 0.02
-1.17
1.53
Debt-to-EBITDA -0.02
IMGN's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. IMGN: -0.02 )
Ranked among companies with meaningful Debt-to-EBITDA only.
IMGN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.81  Med: -0.42 Max: -0.02
Current: -0.02
-0.81
-0.02
Piotroski F-Score: 4
Altman Z-Score: -1.28
Beneish M-Score: -4.15
WACC vs ROIC
23.37%
43.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -147.52
IMGN's Operating Margin % is ranked lower than
53% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. IMGN: -147.52 )
Ranked among companies with meaningful Operating Margin % only.
IMGN' s Operating Margin % Range Over the Past 10 Years
Min: -447.86  Med: -162.45 Max: -50.42
Current: -147.52
-447.86
-50.42
Net Margin % -194.78
IMGN's Net Margin % is ranked lower than
56% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. IMGN: -194.78 )
Ranked among companies with meaningful Net Margin % only.
IMGN' s Net Margin % Range Over the Past 10 Years
Min: -448.24  Med: -162.03 Max: -71.01
Current: -194.78
-448.24
-71.01
ROA % -55.66
IMGN's ROA % is ranked lower than
67% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. IMGN: -55.66 )
Ranked among companies with meaningful ROA % only.
IMGN' s ROA % Range Over the Past 10 Years
Min: -55.66  Med: -36.91 Max: -25.65
Current: -55.66
-55.66
-25.65
ROC (Joel Greenblatt) % -952.80
IMGN's ROC (Joel Greenblatt) % is ranked lower than
58% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. IMGN: -952.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IMGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -952.8  Med: -415.32 Max: -150
Current: -952.8
-952.8
-150
3-Year Revenue Growth Rate 18.90
IMGN's 3-Year Revenue Growth Rate is ranked higher than
75% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. IMGN: 18.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IMGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -47.7  Med: 1.5 Max: 115.4
Current: 18.9
-47.7
115.4
3-Year EBITDA Growth Rate 1.50
IMGN's 3-Year EBITDA Growth Rate is ranked lower than
53% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. IMGN: 1.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IMGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -296.3  Med: -0.1 Max: 72.2
Current: 1.5
-296.3
72.2
3-Year EPS without NRI Growth Rate -5.70
IMGN's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. IMGN: -5.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IMGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -263.4  Med: 0 Max: 75.7
Current: -5.7
-263.4
75.7
GuruFocus has detected 2 Warning Signs with Immunogen Inc IMGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IMGN's 30-Y Financials

Financials (Next Earnings Date: 2018-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

IMGN Guru Trades in Q3 2017

Joel Greenblatt 243,949 sh (New)
John Paulson Sold Out
PRIMECAP Management 3,823,300 sh (-1.52%)
Ken Fisher 248,576 sh (-2.98%)
Jim Simons 524,340 sh (-27.41%)
» More
Q4 2017

IMGN Guru Trades in Q4 2017

Paul Tudor Jones 18,321 sh (New)
Jim Simons 1,093,240 sh (+108.50%)
PRIMECAP Management 3,823,300 sh (unchged)
Joel Greenblatt Sold Out
Ken Fisher 158,476 sh (-36.25%)
» More
Q1 2018

IMGN Guru Trades in Q1 2018

Jim Simons 4,805,940 sh (+339.61%)
PRIMECAP Management 3,823,300 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 136,925 sh (-13.60%)
» More
Q2 2018

IMGN Guru Trades in Q2 2018

Steven Cohen 2,055,933 sh (New)
Jim Simons 6,525,300 sh (+35.78%)
PRIMECAP Management 3,823,300 sh (unchged)
Ken Fisher 136,808 sh (-0.09%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:IMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Reduce -0.09%$9.52 - $12.15 $ 9.29-12%136,808
Ken Fisher 2018-03-31 Reduce -13.60%$6.7 - $12.95 $ 9.29-6%136,925
Ken Fisher 2017-12-31 Reduce -36.25%$5.07 - $7.92 $ 9.2951%158,476
Joel Greenblatt 2017-12-31 Sold Out 0.03%$5.07 - $7.92 $ 9.2951%0
Ken Fisher 2017-09-30 Reduce -2.98%$5.4 - $8.47 $ 9.2940%248,576
Joel Greenblatt 2017-09-30 New Buy0.03%$5.4 - $8.47 $ 9.2940%243,949
John Paulson 2017-09-30 Sold Out 0.02%$5.4 - $8.47 $ 9.2940%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SGMO, XSWX:SFZN, NAS:INVA, SZSE:002275, SZSE:000403, NAS:BOLD, NAS:XNCR, NAS:EDIT, XPAR:DBV, OCSE:ALK B, SHSE:600645, XTER:BIO3, TSE:4565, NAS:TBPH, NAS:WVE, NAS:GTHX, OSTO:VITR, XKRX:005250, SZSE:300149, NAS:RGEN » details
Traded in other countries:IMU.Germany,
Headquarter Location:USA
Immunogen Inc is a clinical-stage biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products.

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies.

Ratios

vs
industry
vs
history
PB Ratio 15.28
IMGN's PB Ratio is ranked lower than
88% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. IMGN: 15.28 )
Ranked among companies with meaningful PB Ratio only.
IMGN' s PB Ratio Range Over the Past 10 Years
Min: 2.4  Med: 9.14 Max: 110.15
Current: 15.28
2.4
110.15
PS Ratio 14.79
IMGN's PS Ratio is ranked lower than
55% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IMGN: 14.79 )
Ranked among companies with meaningful PS Ratio only.
IMGN' s PS Ratio Range Over the Past 10 Years
Min: 2.67  Med: 15.56 Max: 97.63
Current: 14.79
2.67
97.63
EV-to-EBIT -7.61
IMGN's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. IMGN: -7.61 )
Ranked among companies with meaningful EV-to-EBIT only.
IMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -44  Med: -9.3 Max: -0.3
Current: -7.61
-44
-0.3
EV-to-EBITDA -8.11
IMGN's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. IMGN: -8.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
IMGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -51.8  Med: -10.35 Max: -0.3
Current: -8.11
-51.8
-0.3
EV-to-Revenue 13.51
IMGN's EV-to-Revenue is ranked higher than
52% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. IMGN: 13.51 )
Ranked among companies with meaningful EV-to-Revenue only.
IMGN' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 12.95 Max: 85.5
Current: 13.51
0.8
85.5
Current Ratio 5.76
IMGN's Current Ratio is ranked higher than
59% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. IMGN: 5.76 )
Ranked among companies with meaningful Current Ratio only.
IMGN' s Current Ratio Range Over the Past 10 Years
Min: 0.51  Med: 7.09 Max: 60.86
Current: 5.76
0.51
60.86
Quick Ratio 5.73
IMGN's Quick Ratio is ranked higher than
61% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. IMGN: 5.73 )
Ranked among companies with meaningful Quick Ratio only.
IMGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.51  Med: 6.95 Max: 60.86
Current: 5.73
0.51
60.86
Days Sales Outstanding 0.09
IMGN's Days Sales Outstanding is ranked higher than
100% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. IMGN: 0.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
IMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.09  Med: 11.55 Max: 88.26
Current: 0.09
0.09
88.26

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.60
IMGN's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. IMGN: -15.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -87.6  Med: -12.85 Max: -0.7
Current: -15.6
-87.6
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 25.81
IMGN's Price-to-Net-Cash is ranked lower than
83% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. IMGN: 25.81 )
Ranked among companies with meaningful Price-to-Net-Cash only.
IMGN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.9  Med: 9.24 Max: 239.67
Current: 25.81
0.9
239.67
Price-to-Net-Current-Asset-Value 18.58
IMGN's Price-to-Net-Current-Asset-Value is ranked lower than
82% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. IMGN: 18.58 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
IMGN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.85  Med: 7.61 Max: 78
Current: 18.58
0.85
78
Price-to-Tangible-Book 15.23
IMGN's Price-to-Tangible-Book is ranked lower than
82% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. IMGN: 15.23 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IMGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.8  Med: 5.28 Max: 72.18
Current: 15.23
0.8
72.18
Price-to-Median-PS-Value 0.95
IMGN's Price-to-Median-PS-Value is ranked higher than
51% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. IMGN: 0.95 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IMGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.75 Max: 10.1
Current: 0.95
0.21
10.1
Earnings Yield (Greenblatt) % -13.16
IMGN's Earnings Yield (Greenblatt) % is ranked lower than
63% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. IMGN: -13.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IMGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -321  Med: -10.7 Max: -2.3
Current: -13.16
-321
-2.3

More Statistics

Revenue (TTM) (Mil) $77.03
EPS (TTM) $ -1.27
Beta3.32
Volatility60.52%
52-Week Range $4.80 - 13.41
Shares Outstanding (Mil)149.02

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 59 60 103 301
EBIT (Mil $) -154 -168 -128 99
EBITDA (Mil $) -144 -154 -124 103
EPS ($) -1.11 -1.16 -0.78 0.21
EPS without NRI ($) -1.11 -1.16 -0.78 0.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}